These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 16722814

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Albumin-bound Paclitaxel: in metastatic breast cancer.
    Robinson DM, Keating GM.
    Drugs; 2006; 66(7):941-8. PubMed ID: 16740010
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [Abstract] [Full Text] [Related]

  • 5. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA.
    J Control Release; 2013 Sep 28; 170(3):365-72. PubMed ID: 23770008
    [Abstract] [Full Text] [Related]

  • 6. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
    Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R.
    Cancer Chemother Pharmacol; 2015 Oct 28; 76(4):699-712. PubMed ID: 26231955
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W.
    Lancet Gastroenterol Hepatol; 2017 Apr 28; 2(4):277-287. PubMed ID: 28404157
    [Abstract] [Full Text] [Related]

  • 9. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.
    Gut; 2014 Jun 28; 63(6):974-83. PubMed ID: 24067278
    [Abstract] [Full Text] [Related]

  • 10. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC, Bhatia V.
    Expert Rev Anticancer Ther; 2007 Jul 28; 7(7):919-43. PubMed ID: 17627452
    [Abstract] [Full Text] [Related]

  • 11. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R, Sottotetti F, Trifirò G, Piazza E, Ferzi A, Gambaro A, Spinapolice EG, Pozzi E, Tagliaferri B, Teragni C, Bernardo A.
    Drug Des Devel Ther; 2015 Jul 28; 9():2189-99. PubMed ID: 25931813
    [Abstract] [Full Text] [Related]

  • 12. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ, Soon-Shiong P, Desai N.
    Adv Drug Deliv Rev; 2008 May 22; 60(8):876-85. PubMed ID: 18423779
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM, Gupte SU, Patil SG, Pathak AB, Deshmukh CD, Bhatt N, Haritha C, Govind Babu K, Bondarde SA, Digumarti R, Bajpai J, Kumar R, Bakshi AV, Bhattacharya GS, Patil P, Subramanian S, Vaid AK, Desai CJ, Khopade A, Chimote G, Bapsy PP, Bhowmik S.
    Breast Cancer Res Treat; 2016 Feb 22; 156(1):125-34. PubMed ID: 26941199
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
    Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y.
    Cancer Chemother Pharmacol; 2012 Feb 22; 69(2):457-65. PubMed ID: 21853310
    [Abstract] [Full Text] [Related]

  • 16. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S, Maeda N, Nagashima Y, Kubo H, Sato Y, Matsui H, Inoue Y, Shindo Y, Kanekiyo S, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yoshino S, Hazama S, Oka M, Nagano H.
    Breast Cancer; 2017 Nov 22; 24(6):783-789. PubMed ID: 28439763
    [Abstract] [Full Text] [Related]

  • 17. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ.
    Anticancer Drugs; 2008 Oct 22; 19(9):899-909. PubMed ID: 18766004
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA.
    Clin Breast Cancer; 2007 Dec 22; 7(11):850-6. PubMed ID: 18269774
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD.
    Clin Cancer Res; 2008 Jul 01; 14(13):4200-5. PubMed ID: 18594000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.